Today: 19 May 2026
Browse Category

NYSE:HIMS 6 February 2026 - 18 May 2026

Hims & Hers Sinks Pre-Market After Debt Deal Fuels Dilution Talk

Hims & Hers Sinks Pre-Market After Debt Deal Fuels Dilution Talk

Hims & Hers Health shares fell 4% pre-market Monday after announcing a $300 million convertible note sale, with an option for buyers to purchase another $45 million. The move follows a first-quarter net loss of $92.1 million and a drop in gross margin. Proceeds will help fund the planned $1.15 billion Eucalyptus acquisition and technology investments. The notes mature in 2032 and pay interest twice a year.
18 May 2026
·
Hims & Hers’ GLP-1 Reset Hits the Stock as Investors Reprice Growth Quality

Hims & Hers’ GLP-1 Reset Hits the Stock as Investors Reprice Growth Quality

Hims & Hers Health shares fell 14.6% to $24.89 Tuesday after a Q1 net loss of $92.1 million, reversing a $49.5 million profit a year ago. Revenue rose 4% to $608.1 million, but gross margin dropped to 65% from 73% as the company shifted from compounded GLP-1s to branded drugs like Wegovy and Ozempic. Subscribers climbed to 2.584 million, while monthly revenue per subscriber slipped to $80.
12 May 2026
··
US Stock Market Today After Hours: S&P 500 Hits Fresh Record as CPI Risk Looms

US Stock Market Today After Hours: S&P 500 Hits Fresh Record as CPI Risk Looms

The S&P 500 and Nasdaq closed at record highs Monday, lifted by a surge in semiconductor stocks. After-hours, BuzzFeed soared on news of Byron Allen’s $120 million stake and CEO appointment, while GoPro jumped after announcing a strategic review. Hims & Hers fell following a surprise quarterly loss. Investors await Tuesday’s inflation data amid shifting Fed rate cut expectations.
12 May 2026
·····
Hims & Hers Stock Drops After Surprise Loss as Weight-Loss Pivot Clouds 2026 Outlook

Hims & Hers Stock Drops After Surprise Loss as Weight-Loss Pivot Clouds 2026 Outlook

Hims & Hers Health shares dropped about 10% after the company missed first-quarter revenue estimates and reported a $92.1 million net loss, reversing a profit from a year earlier. Revenue rose 4% to $608.1 million, but gross margin fell to 65% and operating expenses increased. Subscriber count grew 9%, though monthly revenue per user declined. The company raised its 2026 sales forecast but cut its profit outlook.
12 May 2026
··
Hims Stock Faces 15% Earnings Swing as Weight-Loss Pivot Comes Due

Hims Stock Faces 15% Earnings Swing as Weight-Loss Pivot Comes Due

Hims & Hers Health shares jumped 9.3% to $28.03 Friday as options traders bet on a 14.8% swing after next week’s earnings. The company will report first-quarter results after markets close May 11. Analysts remain divided, with price targets ranging from $25 to $32. Hims recently launched a compounded testosterone pill and an AI lab-results tool, and expanded access to FDA-approved weight-loss drugs.
8 May 2026
··
Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health said Thursday its providers can now send prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding branded obesity drug options on its platform. The move follows a similar deal with Novo Nordisk in March. Hims listed Foundayo from $149 a month and Zepbound from $299. The company previously stopped advertising compounded GLP-1s amid tighter U.S. regulations.
23 April 2026
···
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides, removing 12 from a high-risk list and scheduling a July review of seven more. The move follows Hims’ March decision to stop advertising compounded GLP-1 drugs and expand branded offerings through Novo Nordisk. The company acquired a California peptide facility last year to bolster supply.
16 April 2026
···
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
15 April 2026
··
Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins

Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins

Hims & Hers Health shares traded near $23.82 Friday after a volatile week sparked by its new obesity-drug deal with Novo Nordisk. Under the agreement, Hims will sell FDA-approved Wegovy and Ozempic at Novo’s prices and stop advertising compounded GLP-1 drugs. Analysts warn the shift to branded drugs could hurt margins, with Hims needing far more subscriptions to offset lost profits. The FDA and Eli Lilly have stepped up scrutiny of compounded weight-loss drugs.
13 March 2026
·
Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares fell 5.6% to $18.25 Tuesday after Novo Nordisk filed a U.S. patent lawsuit seeking to block sales of compounded versions of its Wegovy weight-loss drug. The FDA has said semaglutide is no longer in shortage, tightening rules on compounding. Hims pulled its $49 compounded semaglutide pill days after launch. Investors await Hims’ earnings on Feb. 23.
10 February 2026
···
Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers Health shares plunged 16% in after-hours trading Monday after the company pulled its $49 compounded semaglutide pill amid a patent lawsuit from Novo Nordisk. The stock touched $16.44 before recovering some losses. Novo seeks a court order to stop sales of unapproved compounded drugs. Leerink Partners cut its price target on Hims, citing uncertainty over future sales of compounded semaglutide.
10 February 2026
···
Dow futures steady as Wall Street braces for delayed jobs report and CPI after tech jitters

Dow futures steady as Wall Street braces for delayed jobs report and CPI after tech jitters

Dow futures rose 46 points premarket Monday while S&P 500 and Nasdaq 100 futures slipped. Kroger jumped 6% after a report naming Greg Foran as incoming CEO. Hims & Hers fell after pulling its $49 weight-loss pill following regulatory pressure. Traders awaited delayed January payrolls data and Friday’s CPI report.
9 February 2026
········
Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly shares rose 3.7% to $1,058.18 Friday after Hims & Hers said it would halt sales of a compounded weight-loss pill following an FDA warning. U.S. regulators said they will crack down on mass-marketed, non-approved GLP-1 drugs. The FDA threatened legal action against violators and referred Hims to the Justice Department. Investors are watching for enforcement impact on obesity-drug pricing.
8 February 2026
···
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
7 February 2026
··
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
7 February 2026
····
Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers Health shares fell 2.6% to $22.88 Friday after launching a $49 compounded version of Novo Nordisk’s Wegovy weight-loss pill. Novo called the move “illegal mass compounding” and threatened legal action, while the FDA warned it would act against unapproved copycat drugs. Hims said its pill uses “liposomal technology” to aid absorption but gave no details. Nearly a third of Hims shares are out on loan for short bets.
6 February 2026
·
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
····
1 2

Stock Market Today

  • Tuesday Notable Options Volume in AEVA, RKLB, DSGN
    May 19, 2026, 3:45 PM EDT. Aeva Technologies (AEVA), Rocket Lab Corp (RKLB), and Design Therapeutics (DSGN) saw significant options trading volume Tuesday. AEVA traded 12,218 contracts, about 54.8% of its average daily share volume, with a standout $25 strike call expiring January 2027. RKLB options hit 139,316 contracts, 52.5% of its average volume; the $150 strike call expiring May 2026 led activity. DSGN saw 5,147 contracts, 51.8% of daily volume, dominated by the $25 strike call expiring December 2026. Options volume reflects investor interest in these stocks within the Russell 3000 and signals potential market moves. Data sourced from StockOptionsChannel.com.

Latest articles

Intel Stock Bounces as Wall Street Rethinks AI Narrative

Intel Stock Bounces as Wall Street Rethinks AI Narrative

19 May 2026
Intel shares climbed 3.3% to $111.69 Tuesday afternoon, rebounding after five sessions of losses as Citi and Benchmark raised price targets, citing stronger CPU demand. Trading volume topped 112 million shares. The move came ahead of Nvidia’s earnings, which options traders expect to trigger a major market shift. Intel CEO Lip-Bu Tan was set to speak at a J.P. Morgan conference later in the day.
Pinterest shares erase post-earnings gains

Pinterest shares erase post-earnings gains

19 May 2026
Pinterest shares fell about 6% Tuesday, trading at $18.74 by 3:05 p.m. EDT, erasing gains from its May earnings rally. The drop outpaced declines in Meta, Snap, and Reddit as the Nasdaq and S&P 500 also slipped. Pinterest reported Q1 revenue of $1.008 billion, up 18%, with a net loss of $74 million. The company forecast Q2 revenue above analyst expectations.
Blue Bird Drops 10% on Pension Charge Update

Blue Bird Drops 10% on Pension Charge Update

19 May 2026
Blue Bird shares dropped 9.6% to $65.75 Tuesday after a new SEC filing revealed an expected material non-cash pension settlement charge for the fiscal third quarter. The company will transfer about $94 million in pension liabilities to Pacific Life via group annuity contracts, affecting 2,044 participants. The move follows recent guidance increases and analyst upgrades. Blue Bird said the transactions will be funded entirely by plan assets.
Go toTop